What You Should Know:
– Cleerly, a pioneer in advanced cardiovascular imaging, has announced the successful closure of its Series C extension funding round, raising a total of $106M led by Insight Partners, with participation from Battery Ventures and existing investors.
– The funding will enable Cleerly to expand its reach and make its AI-powered cardiac care solutions accessible to more patients as well as invest in research and clinical trials to further validate the effectiveness of its technology.
Expanding Access to Advanced Cardiac Care
Cleerly is committed to establishing a new standard of care for heart disease by leveraging its FDA-cleared, AI-driven technology. The company’s advanced non-invasive computed tomography (CT) imaging platform enables comprehensive phenotyping of coronary artery disease, providing clinicians with detailed insights to improve patient outcomes.
Cleerly’s AI-powered platform is transforming cardiac care by:
- Improving diagnostic accuracy: Providing detailed and precise assessments of coronary artery disease.
- Enabling early detection: Identifying individuals at risk of heart disease before symptoms develop.
- Personalizing treatment plans: Guiding tailored treatment strategies based on individual patient needs.
- Improving patient outcomes: Reducing the risk of heart attacks and other cardiovascular events.
Building on Recent Achievements
This funding comes on the heels of significant milestones for Cleerly, including:
- Medicare coverage: Securing Medicare coverage for its advanced plaque analysis, expanding access to its technology for a wider patient population.
- CPT Category I code: Obtaining a Category I Current Procedural Terminology (CPT) code for its advanced plaque analysis, facilitating reimbursement and wider adoption.
James K. Min, MD, Founder and CEO of Cleerly, expressed his enthusiasm about the financing, stating, “We are thrilled to receive this investment from Insight Partners, marking a significant milestone for Cleerly. This funding will allow us to expand our commercial reach, which is especially germane following our recent achievements in attaining Medicare coverage and a CPT Category I code for advanced plaque analysis. We are very excited to see our purpose-driven mission come to life, making advanced cardiac care accessible to more patients and working towards our goal of eliminating heart attacks.”
